Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin with or without saxagliptin versus glimepiride added to metformin in adults with type 2 diabetes
2015-002376-24Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2015
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin plus metformin, Dapagliflozin plus saxagliptin plus metformin and Glimepiride plus metformin (3 arms). Primary endpoint: Change in HbA1c from baseline to Week 52. Started Jul 2015; status: completed.
02
Drugs
dapagliflozinsaxagliptinglimepiridemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-002376-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002376-24.